Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mucocutaneous Lymph Node Syndrome | 11 | 2021 | 24 | 2.400 |
Why?
|
| Strongylida Infections | 2 | 2022 | 25 | 0.910 |
Why?
|
| Angiostrongylus cantonensis | 2 | 2022 | 32 | 0.900 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2019 | 201 | 0.730 |
Why?
|
| Microcephaly | 2 | 2016 | 19 | 0.690 |
Why?
|
| Bacteremia | 1 | 2019 | 30 | 0.680 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 352 | 0.610 |
Why?
|
| Doxycycline | 1 | 2017 | 30 | 0.610 |
Why?
|
| Infant | 13 | 2022 | 1046 | 0.580 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 142 | 0.550 |
Why?
|
| Bacteria | 1 | 2019 | 255 | 0.540 |
Why?
|
| Child | 16 | 2021 | 3131 | 0.500 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 103 | 0.500 |
Why?
|
| Child, Preschool | 12 | 2020 | 1418 | 0.480 |
Why?
|
| Staphylococcus aureus | 2 | 2010 | 75 | 0.360 |
Why?
|
| Osteomyelitis | 1 | 2010 | 17 | 0.360 |
Why?
|
| Cost of Illness | 1 | 2010 | 76 | 0.350 |
Why?
|
| Echocardiography | 3 | 2019 | 144 | 0.340 |
Why?
|
| Neoplasms | 1 | 2019 | 1103 | 0.340 |
Why?
|
| Streptococcus pneumoniae | 1 | 2009 | 30 | 0.340 |
Why?
|
| Pneumococcal Infections | 1 | 2009 | 29 | 0.330 |
Why?
|
| Staphylococcal Infections | 1 | 2010 | 58 | 0.330 |
Why?
|
| Hawaii | 8 | 2020 | 1929 | 0.330 |
Why?
|
| Brain | 1 | 2016 | 1346 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 290 | 0.300 |
Why?
|
| Antibodies, Viral | 2 | 2021 | 262 | 0.300 |
Why?
|
| Adolescent | 9 | 2019 | 5363 | 0.300 |
Why?
|
| Incidence | 6 | 2021 | 922 | 0.300 |
Why?
|
| Hospitalization | 3 | 2010 | 388 | 0.290 |
Why?
|
| Female | 16 | 2022 | 20969 | 0.290 |
Why?
|
| Humans | 24 | 2022 | 37093 | 0.290 |
Why?
|
| Infant, Newborn | 5 | 2022 | 894 | 0.280 |
Why?
|
| Aspirin | 2 | 2013 | 49 | 0.280 |
Why?
|
| Male | 15 | 2022 | 20025 | 0.270 |
Why?
|
| Age Distribution | 4 | 2010 | 225 | 0.260 |
Why?
|
| Antirheumatic Agents | 1 | 2005 | 31 | 0.250 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 121 | 0.240 |
Why?
|
| Chickenpox Vaccine | 1 | 2022 | 2 | 0.220 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 356 | 0.220 |
Why?
|
| Exanthema | 1 | 2022 | 10 | 0.220 |
Why?
|
| Chickenpox | 1 | 2022 | 6 | 0.220 |
Why?
|
| Herpes Zoster | 1 | 2022 | 12 | 0.220 |
Why?
|
| Eosinophilia | 1 | 2022 | 18 | 0.220 |
Why?
|
| Retrospective Studies | 6 | 2020 | 2026 | 0.220 |
Why?
|
| Neutralization Tests | 1 | 2021 | 53 | 0.200 |
Why?
|
| Coronary Aneurysm | 2 | 2019 | 3 | 0.200 |
Why?
|
| Coronary Vessels | 2 | 2019 | 85 | 0.200 |
Why?
|
| Cluster Analysis | 1 | 2021 | 195 | 0.190 |
Why?
|
| Albendazole | 1 | 2020 | 5 | 0.190 |
Why?
|
| Pneumonia, Staphylococcal | 2 | 2010 | 3 | 0.190 |
Why?
|
| Anthelmintics | 1 | 2020 | 18 | 0.180 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 53 | 0.180 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2013 | 19 | 0.180 |
Why?
|
| Gram-Positive Bacteria | 1 | 2019 | 14 | 0.170 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2010 | 56 | 0.170 |
Why?
|
| Gram-Negative Bacteria | 1 | 2019 | 22 | 0.170 |
Why?
|
| Population Surveillance | 1 | 2020 | 238 | 0.160 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2017 | 9 | 0.160 |
Why?
|
| Elastin | 1 | 2017 | 40 | 0.150 |
Why?
|
| Matrix Metalloproteinases | 1 | 2017 | 48 | 0.150 |
Why?
|
| Sex Distribution | 2 | 2010 | 215 | 0.150 |
Why?
|
| Double-Blind Method | 1 | 2017 | 286 | 0.150 |
Why?
|
| Risk Assessment | 3 | 2010 | 753 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 268 | 0.140 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2016 | 33 | 0.140 |
Why?
|
| Placenta | 1 | 2016 | 97 | 0.130 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 610 | 0.130 |
Why?
|
| Mothers | 1 | 2016 | 181 | 0.120 |
Why?
|
| Pregnancy | 2 | 2016 | 1549 | 0.120 |
Why?
|
| Appendicitis | 1 | 2013 | 17 | 0.120 |
Why?
|
| Prospective Studies | 1 | 2017 | 1378 | 0.110 |
Why?
|
| Community-Acquired Infections | 2 | 2010 | 22 | 0.110 |
Why?
|
| Wind | 1 | 2011 | 10 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2020 | 1492 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2013 | 149 | 0.100 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 9 | 0.090 |
Why?
|
| Methicillin Resistance | 1 | 2010 | 11 | 0.090 |
Why?
|
| Animals | 3 | 2022 | 15081 | 0.090 |
Why?
|
| Probability | 1 | 2010 | 78 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 144 | 0.080 |
Why?
|
| Fever | 2 | 2008 | 57 | 0.080 |
Why?
|
| Immunoglobulin G | 2 | 2021 | 237 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 974 | 0.080 |
Why?
|
| Poisson Distribution | 1 | 2005 | 38 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 108 | 0.060 |
Why?
|
| Adult | 3 | 2016 | 11712 | 0.060 |
Why?
|
| Length of Stay | 1 | 2005 | 185 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2003 | 14 | 0.060 |
Why?
|
| Registries | 1 | 2005 | 335 | 0.060 |
Why?
|
| Paralysis | 1 | 2022 | 4 | 0.050 |
Why?
|
| Herpesvirus 3, Human | 1 | 2022 | 12 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2002 | 13 | 0.050 |
Why?
|
| Burkitt Lymphoma | 1 | 2002 | 23 | 0.050 |
Why?
|
| Vaccines, Attenuated | 1 | 2022 | 72 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2003 | 90 | 0.050 |
Why?
|
| Torque teno virus | 1 | 2002 | 10 | 0.050 |
Why?
|
| Postpartum Period | 1 | 2022 | 66 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2002 | 15 | 0.050 |
Why?
|
| Ammonium Chloride | 1 | 2021 | 4 | 0.050 |
Why?
|
| DNA Virus Infections | 1 | 2002 | 16 | 0.050 |
Why?
|
| Convalescence | 1 | 2021 | 7 | 0.050 |
Why?
|
| Defective Viruses | 1 | 2021 | 11 | 0.050 |
Why?
|
| New Zealand | 1 | 2021 | 21 | 0.050 |
Why?
|
| Prevalence | 3 | 2016 | 1455 | 0.050 |
Why?
|
| Italy | 1 | 2021 | 22 | 0.050 |
Why?
|
| Lentivirus | 1 | 2021 | 21 | 0.050 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2021 | 20 | 0.050 |
Why?
|
| Republic of Korea | 1 | 2021 | 107 | 0.050 |
Why?
|
| Vero Cells | 1 | 2021 | 93 | 0.050 |
Why?
|
| Virus Integration | 1 | 2002 | 58 | 0.050 |
Why?
|
| Monte Carlo Method | 1 | 2021 | 57 | 0.050 |
Why?
|
| Point Mutation | 1 | 2021 | 93 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2021 | 136 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2021 | 158 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2021 | 188 | 0.050 |
Why?
|
| Hospitals | 1 | 2021 | 86 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2005 | 1369 | 0.050 |
Why?
|
| Linear Models | 1 | 2021 | 275 | 0.050 |
Why?
|
| Vaccination | 1 | 2022 | 288 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2002 | 234 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 448 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2021 | 859 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 149 | 0.040 |
Why?
|
| Acute Disease | 2 | 2013 | 147 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 3562 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 601 | 0.040 |
Why?
|
| Blood Banks | 1 | 2016 | 10 | 0.040 |
Why?
|
| Time Factors | 1 | 2021 | 1742 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2016 | 82 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 935 | 0.030 |
Why?
|
| HIV-1 | 1 | 2021 | 706 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 2013 | 5 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2013 | 62 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 217 | 0.030 |
Why?
|
| United States | 1 | 2021 | 4223 | 0.020 |
Why?
|
| Seasons | 1 | 2011 | 112 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 305 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2010 | 20 | 0.020 |
Why?
|
| California | 1 | 2011 | 476 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2008 | 25 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 47 | 0.020 |
Why?
|
| Half-Life | 1 | 2008 | 54 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 88 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 108 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2008 | 112 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2008 | 99 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 4268 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2003 | 47 | 0.010 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2002 | 13 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2002 | 33 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2002 | 65 | 0.010 |
Why?
|
| HIV | 1 | 2002 | 98 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 214 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 448 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 182 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2002 | 304 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2002 | 474 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 997 | 0.010 |
Why?
|
| Virus Replication | 1 | 2002 | 278 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 1568 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 420 | 0.010 |
Why?
|
| HIV Infections | 1 | 2002 | 2303 | 0.010 |
Why?
|